// App-Quantinova.ai

10507 : Results of SARC 022, a phase II multicenter study of linsitinib in pediatric and adult wild-type (WT) gastrointestinal stromal tumors (GIST).

Researchers

Presenter

  • Margaret von Mehren

Principal Investigators

  • Suzanne George

  • Michael C. Heinrich

  • Katherine A. Janeway

  • Lori Rink

  • Kristen N. Ganjoo

  • Jian Qin Yu

  • Jeffrey T. Yap

  • John Joseph Wright

Medical Centers

  • Dana-Farber Cancer Institute, Boston, MA

  • Fox Chase Cancer Center, Philadelphia, PAOHSU Knight Cancer Institute and Portland VA Medical Center, Portland, ORStanford University, Palo Alto, CA

  • National Cancer Institute, Rockville, MD

  • University of Michigan, Ann Arbor, MI

  • Hunstman Cancer Institute of Utah, Salt Lake City, UT

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Gastrointestinal stromal tumor

  • PDGFRA rearrangement

Biomarkers

  • 18F-fluorodeoxyglucose

  • Platelet Derived Growth Factor Receptor Alpha

  • Hemoglobin A1c

  • KIT Proto-Oncogene, Receptor Tyrosine Kinase

Drug/Treatment

  • Linsitinib

Outcome

  • Positive

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT01560260

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved